Denali Therapeutics Valuation
| DNLI Stock | USD 14.43 0.18 1.23% |
At this time, the firm appears to be fairly valued. Denali Therapeutics shows a prevailing Real Value of $14.04 per share. The current price of the firm is $14.43. Our model computes the value of Denali Therapeutics from reviewing the firm fundamentals such as Shares Owned By Institutions of 90.99 %, shares owned by insiders of 9.57 %, and Current Valuation of 1.34 B as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Denali Therapeutics' valuation include:
Price Book 1.7253 | Enterprise Value | Enterprise Value Ebitda (8.66) | Price Sales 3.6 K | Enterprise Value Revenue 2.8 K |
Fairly Valued
Today
Please note that Denali Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Denali Therapeutics is based on 3 months time horizon. Increasing Denali Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Denali Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Denali Stock. However, Denali Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.43 | Real 14.04 | Target 39.73 | Hype 14.43 | Naive 15.12 |
The intrinsic value of Denali Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Denali Therapeutics' stock price.
Estimating the potential upside or downside of Denali Therapeutics helps investors to forecast how Denali stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Denali Therapeutics more accurately as focusing exclusively on Denali Therapeutics' fundamentals will not take into account other important factors: When choosing an evaluation method for Denali Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Denali Therapeutics Cash |
|
Denali Valuation Trend
Denali Therapeutics' real value analysis enables investors to forecast the earnings more efficiently. Using both Denali Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Denali Therapeutics Total Value Analysis
Denali Therapeutics is currently expected to have valuation of 1.34 B with market capitalization of 2.12 B, debt of 42.29 M, and cash on hands of 1.07 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Denali Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.34 B | 2.12 B | 42.29 M | 1.07 B |
Denali Therapeutics Asset Utilization
One of the ways to look at asset utilization of Denali is to check how much profit was generated for every dollar of assets it reports. Denali Therapeutics shows a negative utilization of assets of -0.25 percent, losing $0.002482 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Denali Therapeutics shows how discouraging it operates for each dollar spent on its assets.Denali Therapeutics Ownership Allocation
Denali Therapeutics holds a total of 145.22 Million outstanding shares. The majority of Denali Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Denali Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Denali Therapeutics. Please pay attention to any change in the institutional holdings of Denali Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that almost eight hundred thirteen thousand two hundred four invesors are currently shorting Denali Therapeutics expressing very little confidence in its future performance.Denali Therapeutics Profitability Analysis
Net Loss for the year was (422.77 M) with loss before overhead, payroll, taxes, and interest of (396.44 M).About Denali Therapeutics Valuation
An absolute valuation paradigm, as applied to Denali Stock, attempts to find the value of Denali Therapeutics based on its fundamental and basic technical indicators. By analyzing Denali Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Denali Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Denali Therapeutics. We calculate exposure to Denali Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Denali Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 360.9 M | 378.9 M | |
| Pretax Profit Margin | (0.40) | (0.42) | |
| Operating Profit Margin | (0.54) | (0.56) | |
| Net Loss | (0.40) | (0.42) | |
| Gross Profit Margin | 0.85 | 0.90 |
Denali Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 164.5 M |
Denali Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Denali Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Denali we look at many different elements of the entity such as Denali's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Denali Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Denali Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Denali Therapeutics' worth.Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |